Literature DB >> 23863455

Strategies in the development of vaccines to prevent infections with group A streptococcus.

Michael F Good1, Michael R Batzloff, Manisha Pandey.   

Abstract

There has long been interest and demand for the development of a vaccine to prevent infections caused by the Gram-positive organism group A streptococcus. Despite numerous efforts utilizing advanced approaches such as genomics, proteomics and bio-informatics, there is currently no vaccine. Here we review various strategies employed to achieve this goal. We also discuss the approach that we have pursued, a non-host reactive, conformationally constrained minimal B cell epitope from within the C-repeat region of M-protein, and the potential limitations in moving forward.

Entities:  

Keywords:  J8-DT; group A streptococcus; rheumatic fever; rheumatic heart disease; vaccination

Mesh:

Substances:

Year:  2013        PMID: 23863455      PMCID: PMC3981849          DOI: 10.4161/hv.25506

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  50 in total

1.  Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies.

Authors:  J B Zabriskie; T Poon-King; M S Blake; F Michon; M Yoshinaga
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

2.  Mapping a conserved conformational epitope from the M protein of group A streptococci.

Authors:  W A Relf; J Cooper; E R Brandt; W A Hayman; R F Anders; S Pruksakorn; B Currie; A Saul; M F Good
Journal:  Pept Res       Date:  1996 Jan-Feb

3.  Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes.

Authors:  James B Dale; Thomas Penfound; Edna Y Chiang; Valerie Long; Stanford T Shulman; Bernard Beall
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

Review 4.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

5.  Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.

Authors:  Michael R Batzloff; Huaru Yan; Mark R Davies; Jon Hartas; George H Lowell; Gregory White; David S Burt; Tomas Leanderson; Michael F Good
Journal:  J Infect Dis       Date:  2005-09-09       Impact factor: 5.226

6.  Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus.

Authors:  Y Ji; B Carlson; A Kondagunta; P P Cleary
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

7.  Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus.

Authors:  W A Hayman; E R Brandt; W A Relf; J Cooper; A Saul; M F Good
Journal:  Int Immunol       Date:  1997-11       Impact factor: 4.823

8.  Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci.

Authors:  E R Brandt; W A Hayman; B Currie; S Pruksakorn; M F Good
Journal:  Vaccine       Date:  1997-11       Impact factor: 3.641

9.  Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins.

Authors:  L Guilherme; E Cunha-Neto; V Coelho; R Snitcowsky; P M Pomerantzeff; R V Assis; F Pedra; J Neumann; A Goldberg; M E Patarroyo
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

10.  Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1957-10-01       Impact factor: 14.307

View more
  8 in total

1.  Epidemiology Analysis of Streptococcus pyogenes in a Hospital in Southern Taiwan by Use of the Updated emm Cluster Typing System.

Authors:  Chuan Chiang-Ni; Po-Xing Zheng; Shu-Ying Wang; Pei-Jane Tsai; Woei-Jer Chuang; Yee-Shin Lin; Ching-Chuan Liu; Jiunn-Jong Wu
Journal:  J Clin Microbiol       Date:  2015-11-11       Impact factor: 5.948

Review 2.  Necrotizing pneumonia: an emerging problem in children?

Authors:  I Brent Masters; Alan F Isles; Keith Grimwood
Journal:  Pneumonia (Nathan)       Date:  2017-07-25

Review 3.  Rheumatic heart disease: infectious disease origin, chronic care approach.

Authors:  Judith M Katzenellenbogen; Anna P Ralph; Rosemary Wyber; Jonathan R Carapetis
Journal:  BMC Health Serv Res       Date:  2017-11-29       Impact factor: 2.655

4.  Streptolysin O derived from Streptococcus pyogenes inhibits RANKL‑induced osteoclastogenesis through the NF‑κB signaling pathway.

Authors:  Jin Yi; Ruohui Tang; Jing Yang; Yueqi Chen; Jun Fei
Journal:  Mol Med Rep       Date:  2018-11-15       Impact factor: 2.952

5.  Streptolysin O Rapidly Impairs Neutrophil Oxidative Burst and Antibacterial Responses to Group A Streptococcus.

Authors:  Satoshi Uchiyama; Simon Döhrmann; Anjuli M Timmer; Neha Dixit; Mariam Ghochani; Tamara Bhandari; John C Timmer; Kimberly Sprague; Juliane Bubeck-Wardenburg; Scott I Simon; Victor Nizet
Journal:  Front Immunol       Date:  2015-11-16       Impact factor: 7.561

6.  Predicted Coverage and Immuno-Safety of a Recombinant C-Repeat Region Based Streptococcus pyogenes Vaccine Candidate.

Authors:  Celia McNeilly; Samantha Cosh; Therese Vu; Jemma Nichols; Anna Henningham; Andreas Hofmann; Anne Fane; Pierre R Smeesters; Catherine M Rush; Louise M Hafner; Natkuman Ketheesan; Kadaba S Sriprakash; David J McMillan
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

Review 7.  Streptococcal toxic shock syndrome in the intensive care unit.

Authors:  Marylin Schmitz; Xavier Roux; Benedikt Huttner; Jérôme Pugin
Journal:  Ann Intensive Care       Date:  2018-09-17       Impact factor: 6.925

8.  Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial.

Authors:  Silvana Sekuloski; Michael R Batzloff; Paul Griffin; William Parsonage; Suzanne Elliott; Jon Hartas; Peter O'Rourke; Louise Marquart; Manisha Pandey; Fran A Rubin; Jonathan Carapetis; James McCarthy; Michael F Good
Journal:  PLoS One       Date:  2018-07-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.